Brainomix’s AI Stroke Software Boosts Recovery Rates Significantly

Innovative AI technology from Brainomix has made significant strides in improving stroke recovery rates, according to a recent study by the Royal Berkshire Hospital. The findings reveal that the company’s Brainomix 360 Stroke software has increased the percentage of stroke patients achieving functional independence from 16% to 48%. This advancement has garnered considerable attention in the media and among healthcare professionals.

The study highlighted that the use of Brainomix 360 Stroke led to a more than 50% rise in the application of mechanical thrombectomy, a critical treatment that can drastically change outcomes for stroke patients. This comprehensive platform utilizes advanced AI algorithms to provide real-time interpretations of brain scans, aiding clinicians in making timely treatment decisions in both specialized and general hospitals.

Transforming Stroke Care with AI

David Hargroves, NHS Clinical Director for Stroke, emphasized the importance of rapid diagnosis and treatment for stroke patients. “This AI decision support technology is revolutionising how we help people who have been affected by stroke,” he stated. Hargroves pointed out that patients can lose approximately 2 million brain cells each minute during a stroke, underscoring the necessity for swift action.

Brainomix’s technology is designed to support healthcare professionals by streamlining the diagnostic process. The software enhances the capabilities of doctors and other NHS staff, allowing them to make faster and more informed treatment decisions. As the technology continues to gain traction, its real-world impact is becoming increasingly evident.

Validation Through Real-World Evidence

Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, expressed pride in the advancements made possible by the company’s software. “Brainomix is helping clinicians every day improve the level of care they can deliver to stroke patients in the UK and worldwide,” he stated. He added that the growing body of published real-world evidence validates the effectiveness of their technology in enhancing patient outcomes.

Brainomix has emerged as a leading AI healthcare company in the UK, having successfully developed its technology from initial concepts to market launch. The company has established partnerships with organizations such as NHS England and the Health Innovation Network, further solidifying its position in the healthcare technology landscape.

With its software widely deployed across the UK and Europe, Brainomix 360 Stroke is recognized as the market leader. Additionally, the technology has been validated by various top-tier stroke institutions in the United States, demonstrating its potential to make a significant impact on stroke care globally.

The ongoing focus on AI in healthcare, particularly in stroke treatment, highlights the transformative potential of technology in improving patient outcomes. As Brainomix continues to expand its influence, the healthcare community eagerly anticipates further advancements that will enhance care for stroke patients around the world.